Rare Daily Staff
Centogene said it will open its first U.S.-based rare disease laboratory in Cambridge, Massachusetts to serve as the central point of contact for its collaboration partners that leverage its diagnostic services in the United States.
The new facility will feature a state-of-the-art high-throughput genetic testing laboratory along with biochemical, proteomic, metabolomic and genetic analysis capabilities from various patient sample materials.
“Centogene is one hundred percent focused on translating rare disease genetics into medical breakthroughs and we are thrilled to continue our global expansion into the preeminent biotech hub of Cambridge,” said Arndt Rolfs, CEO and founder of Centogene.
An estimated 350 million people worldwide suffer from rare diseases, with 30 percent not living to see their fifth birthday. With a diagnosis often taking more than eight years, there is tremendous unmet need in early diagnosis and treatment options.
Centogene provides solutions that target early diagnostics and support for pharmaceutical companies to help identify and accelerate treatments. Its biomarker technology supports measuring the effectiveness of treatment and is supportive in the development toward more personalized medicines.
June 5, 2018
Photo: Arndt Rolfs, CEO and founder of Centogene